Dieser Anti-TAG-72 (Minretumomab Biosimilar)-Antikörper ist ein Humanized-Monoklonal-Antikörper zum Nachweis von TAG-72 (Minretumomab Biosimilar) in FACS und in vivo. Geeignet für Human.
Minretumomab Biosimilar uses the same protein sequences as the therapeutic antibody minretumomab. Minretumomab is a mouse monoclonal antibody that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers. A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric and humanized minretumomab, as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.